Stay updated with breaking news from Matthewa Powell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite advanced ovarian and endometrial cancer still being accompanied by a poor prognosis and remaining largely difficult-to-treat diseases, optimism among clinicians has steadily ramped up in recent years with the development of multiple new promising agents and treatment regimens.
Led by principal investigator David Mutch, MD, researchers at Washington University School of Medicine in St. Louis have received a prestigious Specialized Programs of Research Excellence (SPORE) grant in endometrial cancer from the National Cancer Institute of the National Institutes of Health (NIH).
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.
Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.